On September 29, 2025, Soligenix, Inc. (NASDAQ: SNGX) announced the closing of a previously announced public offering, selling 5,555,560 shares of common stock and an equal number of warrants at a combined purchase price of $1.35 per share, generating gross proceeds of approximately $7.5 million before fees and expenses.
The proceeds will extend Soligenix’s cash runway through the end of 2026, providing the company with the financial resources needed to fund research and development, commercialization activities, working capital and general corporate purposes.
This financing event supports Soligenix’s strategic focus on advancing its late‑stage pipeline—including HyBryte for cutaneous T-cell lymphoma and its Innate Defense Regulator platform—while ensuring liquidity for key inflection points in the coming years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.